Treatment of knee osteoarthritis with combination of traumeel s and zeel t: review mozart clinical investigation
Keywords:osteoarthritis, knee joint, Traumeel S, Zeel T, intraarticular injections, MOZArT investigation
AbstractTraditional treatment of osteoarthritis is focused on the symptoms’ decrease using pain-killers, nonsteroid anti-inflammatory drugs (NSAIDs), intraarticular corticosteroid injections, hyaluronic acid and so on. Nevertheless, such a therapy has some limitation due to the possible side effects and contraindications, especially in elderly people with concomitant diseases. Traumeel S consists of 14 components with vegetal and mineral origins, that determine its anti-inflammatory, anti-exudative, anesthetic, restorative and immune-modeling action. Zeel T provides chondroprotective, anti-inflammatory, anesthetic effects that promotes restoration of metabolic and reparative processes in joint cartilage. Goal: to expose the results of multicenter randomized placebo-control double-blind investigation MOZArT («Management of Оsteoarthritis of the Knee with Zeel and Traumeel Injections») to evaluate the efficacy and safety of the intraarticular injections of Traumeel S and Zeel T in comparison with placebo. The methods: 232 patients from 24 centers in USA were involved in the investigation. Patients (119) from the main group took the injection of Traumeel S and Zeel T, 113 participants from control group – physiological solution as a placebo. Three injection of every remedy were carried out with 1-week interval between the injections. WOMAC A scale was used to assess the results. Results: under the conditions of Traumeel S and Zeel T usage significant reducing of pain by 60 % according to WOMAC A scale was observed after 2nd injection and during the following 12 weeks. The effect of mentioned combined therapy was compared with the results of intra-articular corticosteroid and hyaluronic acid injection and peroral diclofenac. Safety profiles of Traumeel S and Zeel T were more optimal in comparison with peroral NSAIDs, without any risk from cardiac-vascular and gastro-intestinal systems.
A multi-center double-blind, randomized, controlled trial (db-RCT) to evaluate the effectiveness and safety of co-administered Traumeel® (Tr14) and Zeel® (Ze14) intra-articular (IA) injections versus IA placebo in patients with moderate-to-serve pain associated with OA of the knee / C. Lozada, E. del Rio, D. Reitberg [et al.] / Arthritis Rheumatol. — 2014. — Vol. 66, Ssuppl. — P. S1266.
Monograph of Traumeel S/ Ed. from English. — M.: Arnebia, 2015. — 80 p.
WOMAC Osteoarthritis Index [web source]. — Access mode: http://www.womac.org/womac/index.htm.
Traumeel vs. diclofenac for reducing pain and improving ankle mobility after acute ankle sprain: A multicentre, randomised, blinded, controlled and non-inferiority trial / C. González de Vega, C. Speed, B. Wolfarth, J. González // Int. J. Clin. Pract. — 2013. — Vol. 67 (10). — P. 979–989, doi: 10.1111/ijcp.12219.
Comparative effectiveness of pharmacologic interventions for knee osteoarthritis a systematic review and network meta-analysis / R. R. Bannuru, Ch. H. Schmid, D. M. Kent [et al.] // Ann. Intern. Med. — 2015. — Vol. 162. — P. 46–54, doi: 10.7326/M14-1231.
Risk-Benefit of Co-Administered Traumeel® (TR14) and Zeel® (ZE14) Intra-Articular (IA) Injections in Patients with Moderate-to-Severe Pain Associated with OA of the Knee (OAK). Poster Presentations THU0441 / C. Lozada, E. del Rio, D. P. Reitberg [et al.]: materials of Annual European Congress EULAR (Rome, 10-13.06.2015) // Ann Rheum Dis. — 2015. — Vol. 74, Suppl. 2. — P. 359, doi: 10.1136/annrheumdis-2015-eular.4268.
The purpose of the Zeel T: Product of monograph / Ed. from English. — Germany, Baden-Baden, Biologische Heilmittel Heel GmbH, 2015. — 56 p.
Copyright (c) 2015 Sergey Popovich
This work is licensed under a Creative Commons Attribution 4.0 International License.
The authors retain the right of authorship of their manuscript and pass the journal the right of the first publication of this article, which automatically become available after 6 months from the date of publication under the terms of Creative Commons Attribution License, which allows others to freely distribute the published manuscript with mandatory linking to authors of the original research and the first publication of this one in this journal.
Authors have the right to enter into a separate supplemental agreement on the additional non-exclusive distribution of manuscript in the form in which it was published by the journal (i.e. to put work in electronic storage of an institution or publish as a part of the book) while maintaining the reference to the first publication of the manuscript in this journal.
The editorial policy of the journal allows authors and encourages manuscript accommodation online (i.e. in storage of an institution or on the personal websites) as before submission of the manuscript to the editorial office, and during its editorial processing because it contributes to productive scientific discussion and positively affects the efficiency and dynamics of the published manuscript citation (see The Effect of Open Access).